Cholate-based nano emulgel of 1,1-dimethylbiguanide can diminish the liver damage in NAFLD induced by high-fat diet

Heba F. Salem1,2, Mohammed M. Nafady1*, Adel A. Ali1, Nermeen M. Khalil1, Amani A. Elsisi1

1Department of Pharmaceutics & Industrial Pharmacy, Faculty of Pharmacy, Beni-Suef University, Beni-Suef, Egypt.
26 October Technological University, Cairo, Egypt.
3Department of Pharmaceutics, Faculty of Pharmacy, Nahda University Beni-Suef, Egypt.

ARTICLE INFO
Received on: 31/01/2023
Accepted on: 10/05/2023
Available Online: 04/07/2023

Key words: Metformin HCl, cholate-based nanovesicles emulgel, rheology study, tumor necrosis factor-alpha, liver targeting.

ABSTRACT
NAFLD (nonalcoholic fatty liver disease) is a widely spread disease that, till now, has no approved therapy, and enhancing the patient’s case depends only on lifestyle modification. In this research, cholate-based 1,1-dimethylbiguanide (metformin HCl) was incorporated into an emulgel to investigate its transdermal effect in treating NAFLD. Metformin HCl cholate-based nanovesicles were prepared with the solvent vaporization technique. Vesicles are imaged by transmission electron microscope to ensure the vesicles formation, and their charge is detected to inspect their stability. The vesicles were then incorporated into a prepared Carbopol emulgel and then were characterized. Finally, an in vivo study on balb-c mice was performed to inspect its effect in treating NAFLD topically. The resulting vesicles were stable, sphere-shaped, and nonaggregated with a coarse surface. In addition, prepared emulgel was found clear and homogenous with general characteristics suitable for skin application. Furthermore, the rheology study showed a thixotropic performance. Finally, the in vivo study revealed an overall enhancement confirming the liver targeting ability of cholate-based bile salts. Cholate-based nanovesicles emulgel of metformin HCl is an approach for an acceptable level of evidence of effective transdermal treatment of NAFLD.

INTRODUCTION
NAFLD (nonalcoholic fatty liver disease) is considered a comprehensive world health problem nowadays (Bellentani et al., 2010). It includes fatty liver and steatohepatitis starting from liver fatty vacuoles and fibrosis leading to hepatic cancer (Hadizadeh et al., 2017). Until now, no known therapy has been approved for treating NASH (nonalcoholic steatohepatitis) (Sporea et al., 2018). NAFLD in vivo study should be done on a suitable animal model that resembles NAFLD pathogenesis in humans and is caused by the same risk factors (obesity, fatty diet, high sugars, and insulin resistance) (Hadizadeh et al., 2017).

NAFLD pathogenesis comprises abnormality in liver enzymes and lipid profile serum samples, tumor necrosis factor alpha (TNF-α) elevation, and fat vacuolation in liver histology with mild to severe fibrosis (Hadizadeh et al., 2017; Sporea et al., 2018).

Metformin HCl (C4H12ClN5; 3-(diaminomethylidene)-1,1-dimethylguanidine; hydrochloride). It is the hydrochloride salt of biguanide antidiabetics with antihyperglycemic activity. Only 50% of an orally administered dose is absorbed from the gut. Therefore, metformin is a biopharmaceutics class III. Furthermore, it helps to reduce low-density lipoprotein (LDL), cholesterol, and triglycerides (TG) levels. Metformin is not metabolized and is excreted by the renal. Its molecular weight is approximately 165, and its water miscible. Metformin HCl is the drug of choice in treating diabetes mellitus type II (Cicero et al., 2012). Also, recent studies have shown its valuable effect on other diseases such as obesity, cancer, circulatory diseases, and fatty liver (Salem et al., 2022) (Green et al., 2019; Li et al., 2013). Different oral formulations were studied for metformin HCl (Ng and Gupta, 2020), for instance, traditional tablets,
sustained-release tablets (Basak et al., 2008), and floatable gastroretentive tablets (Basak et al., 2007). Though severe gastritis and poor oral absorption are the significant drawbacks of metformin oral administration methods, (Jain and Gupta, 2009) more studies lead to the possibility of topical delivery of metformin HCl through advanced nanodelivery systems (Salem et al., 2022). Metformin is known to enhance insulin resistance besides its TNF-α suppression ability, so that it can be used in treating NAFLD.

Cholate-based nanovesicles are spherical bilayered bile salts-based vesicles that are 5–200 nm in size and can be uni- or multilamellar. In general, cholate-based nanovesicles consist of two layers; the inner layer consists of hydrophilic drugs and (or) antigens, and the outer layer consists of bile salts and (or) hydrophobic drugs. Materials used in the formulation of cholate-based nanovesicles encompass mainly nonionic surfactants and bile salts; lipids such as phosphatidylcholine and cholesterol are also included. It involves nonionic surfactants and exhibits a better quality of transdermal delivery than other nanovesicles (Al-Mahallawi et al., 2015). Bile salts produce extremely stable vesicles for transdermal distribution by acting as electrostatic stabilizers and edge activators with fluidizing effects (El Zaafarany et al., 2010). Cholate-based nanovesicles can be prepared by the solvent vaporization method (Al-Mahallawi et al., 2015). Cholate-based nanovesicles are advanced vesicles (Ahmed et al., 2020) known as liver targeting molecules formed mainly from bile salts and surfactants (Al-Mahallawi et al., 2015). Recently, it was studied to enhance the permeation of metformin through the skin stratum corneum layer and showed stunning results (Salem et al., 2022). So incorporating of cholate-based nanovesicles into an emulgel could be an advanced delivery system that gives a thixotropic behavior with a nongreasy emollient application (Alexander et al., 2013).

The in vivo study of NAFLD should be done on a suitable animal model that resembles NAFLD pathogenesis in humans and is caused by the same risk factors (Hadizadeh et al., 2017). Therefore, balb-c mice were chosen as animal models for NAFLD. However, it is known to resist the change in body weight (Kim et al., 2011; Nishikawa et al., 2007). It reflects a good pathology indication in serum analysis, hepatic histology, and liver weight (Hadizadeh et al., 2017; Rahmadi et al., 2021; Xie et al., 2015).

Aberration of ALT (transaminases alanine aminotransferase) and AST (aspartate aminotransferase) values is frequently associated with NAFLD. Through around 60 transamination reactions, only ALT and AST are clinically significant. In copious studies of NAFLD patients, raised levels of aminotransferase and diabetes have been ascertained as steadfast predictors of fibrosis in patients with a risk of progressing to advanced fibrosis (Harrison et al., 2003).

TNF-α has an indispensable effect on the development of NAFLD due to its proinflammatory influence (Hadizadeh et al., 2017; Jovinge et al., 1998). In addition, it provokes hepatocytes apoptosis and proliferation causing liver fibrosis (Galle, 1997; Yang and Seki, 2015). Moreover, TNF-α increases the TG serum concentrations (Jovinge et al., 1998) and reduces serum HDL-c levels and insulin sensitivity (Tacer et al., 2007). In NAFLD, the serum levels of TNF-α raises, so standardization of its concentration improves insulin sensitivity and NAFLD (Ajmal et al., 2014; Hadizadeh et al., 2017).

In this research, metformin cholate-based nanovesicles emulgel was prepared and characterized as an approach for acceptable level of evidence of effective transdermal treatment of NAFLD in balb-c mice through different mechanisms avoiding the drastic side effects of metformin.

MATERIALS AND METHODS

Metformin HCl was kindly provided by Cid Pharmaceutical Co. (Assuit, Egypt). Span 60 (S60) (sorbitan monostearate), Span 80 (S80) (Sorbitan monoooleate), and Tween 80 (polysorbate 80) are purchased from Oxford Laboratory (El-Nasr Pharmaceutical Chemicals Co., Sohag, Egypt). Sodium deoxycholate (SDC) is purchased from Acros Organics (El-Nasr Pharmaceutical Chemicals Co., Sohag, Egypt). Cholesterol is purchased from Sigma Aldrich, Saint Louis, MO. Methanol and methylene chloride ADWC are purchased from El-Nasr Pharmaceutical Chemicals Co., Sohag, Egypt. Carbopol 940 and polyethylene glycol (PEG 400) were purchased from LOBA Chemie, Mumbai, India. Dimethyl sulfoxide (DMS), triethanolamine, and ethanol were obtained from El-Nasr Pharmaceutical Chemicals Co., Cairo, Egypt. All reagents were of analytical grade and were commercially available.

Standard calibration curve

Stock solution (1 mg/ml) of metformin HCl dissolved in phosphate citrate buffer pH 4 was used to establish a standard calibration curve, and serial dilutions (1 to 8 μg/ml) were prepared. Metformin HCl was analyzed using a UV spectrophotometer at λ max = 233 nm. The absorbances were plotted against the concentrations, and the linear regression equation was calculated.

Formulation of metformin HCl cholate-based bile salts

Metformin HCl cholate-based nanovesicles were formulated through the solvent vaporization method with slight modification (Salem et al., 2022). Concisely, metformin HCl (600 mg) and cholesterol (14 mg) were dissolved in a methanol-to-methylene-chloride (1:2) mixture after addition of 130 mg of span 60 (as a surfactant) and 8 mg of SDC (as an edge activator). The solvents were then completely evaporated by continuous agitation on a magnetic stirrer (IKA, C-MAG HS 7 digital, Germany) at 60°C. The resulting residue was then hydrated with phosphate citrate buffer pH 4 to obtain the cholate-based nanovesicles suspension. Phosphate citrate buffer pH 4 was used because of the metformin HCl tendency to be more soluble in acidic media, while the pH of the skin ranges from 4 to 6 (El-Menshawe et al., 2018).

Morphology of metformin HCl cholate-based nanovesicles by TEM (Transmission electron microscope)

The vesicles morphology was reconnoitered using high-resolution TEM (JEOL Co., JEM-1400; Japan) (negative stain technique) to ensure the successful formation of the cholate-based bile salts. First, the formulation was suitably diluted with distilled water; then, a drip was put above a carbon-coated copper grating and stained with a phosphotungstic dye at 160 KV fast-tracking voltage (El-Menshawe et al., 2018).

Zeta size and potential of metformin HCl cholate-based bile salts

The zeta size and potential of the prepared formulation (diluted with 4 ml distilled water) were detected using the dynamic
light-scattering technique applied by the zeta seizer (Malvern Zetasizer3000, UK) with a fixed angle of 90° at room temperature (25°C) (El-Menshawe et al., 2018).

**Preparation of metformin HCl cholate-based nanovesicles emulgel**

Carbopol 940 (1% w/v) as a gelling agent was kept overnight in water at 4°C, then 15% w/v PEG-400 (polyethylene glycol-400) was added to get a homogeneous gel. The emulsion (o/w type) was prepared by adding the oily phase continuously with stirring to the aqueous phase; span 80 was dissolved in castor oil to prepare the emulsion oil phase, while Tween 80 was dissolved in purified water to prepare the aqueous phase. The oil and aqueous phases of the emulsion were separately heated to 75°C and allowed to cool to room temperature. The emulsion and the carbopol gel were mixed in a 1:1 ratio with mild rousing to obtain the emulgel and then triethanolamine (1%) was dropped to maintain the pH. Finally, a calculated weight of metformin HCl cholate-based nanovesicles equivalent to 600 mg of metformin HCl was incorporated into the obtained emulgel (Mohamed et al., 2019).

**Characterization of metformin HCl cholate-based nanovesicles emulgel**

**Clarity and homogeneity of metformin HCl cholate-based nanovesicles emulgel**

The clarity and homogeneity of the prepared cholate-based nanovesicles emulgel were evaluated visually against white and black backgrounds to evaluate the manifestation of any aggregation or turbidity. The formulation was stored at room temperature (25°C) and reevaluated after 15 days.

**The pH of metformin HCl cholate-based nanovesicles emulgel**

The pH meter (Jenway 3510 pH meter; Staffordshire, UK) was used to determine the cholate-based nanovesicles emulgel pH. Briefly, 1 ml of the prepared cholate-based nanovesicles emulgel was suitably diluted with distilled water (10 ml) and allowed to equilibrate before dipping the pH meter probe (Vani et al., 2018). The pH measurements were implemented in triplicate, and the mean was calculated. The formulation was reevaluated after 15 days of storing at room temperature (25°C).

**Rheology study of metformin HCl cholate-based nanovesicles emulgel**

The viscosity of the prepared emulgel was determined over a wide range of speeds (10–100 rpm) to inspect its rheology behavior using Brookfield viscometer (HBDV-III Ultra; Brookfield Engineering Laboratories, Stoughton, MA) with a suitable spindle (CP 40 model HB). The gap between every two consecutive measurements was 30 seconds and the test was done at room temperature (25°C) (Salem et al., 2021). The hysteresis loops and the grade of pseudoplasticity (Farrow’s constant) were determined using the trapezoidal rule. Then, the area under the down curve was subtracted from the total area under the curve to attain the hysteresis loop area. Farrow’s equation (Eq. 1) was applied to study the flow performance of the gel base,

\[
\log G = N \log F - \log \eta, \quad (1)
\]

where \( G \) is the shear rate (second\(^{-1}\)), \( F \) is the shear stress (dyne/cm\(^2\)), \( \eta \) is the viscosity (cP), and \( N \) is Farrow’s constant.

**Spreadability of metformin HCl cholate-based nanovesicles emulgel**

The formulation spreadability was determined by adding 0.5 g of the prepared metformin HCl cholate-based nanovesicles emulgel between two glass slides with known dimensions (5 × 5 cm). The sample was placed on a premarked circle with a known diameter (1 cm), and the diameter increasing (spreading area) was determined after adding a standard load after 1 minute. The diameter of the spread circle was determined (Abdallah et al., 2021).

**Extradurability of metformin HCl cholate-based nanovesicles emulgel**

The extradurability of the prepared formulation was detected by calculating the area of emulgel extruded from a lacquered aluminum portable tube. The weight of (g) required to extrude about 0.5 cm strip of gel within 10 seconds was documented. Extradurability is directly proportional to the amount of emulgel extruded. Therefore, the extradurability was determined by dividing the load weight (g) by the area (cm\(^2\)).

**Drug content determination of metformin HCl cholate-based nanovesicles emulgel**

One gram of the prepared cholate-based nanovesicles emulgel formulation was transferred to a 100 ml volumetric flask and diluted with phosphate citrate buffer (pH 4) to 100 ml and then allowed to dissolve in a bath sonicator. After complete dissolving, 1 ml of the prepared solution was withdrawn and rediluted to 10 ml with phosphate citrate buffer (pH 4). The sample solution was filtered and then scanned on a UV spectrophotometer at \( \lambda \) 233 nm against phosphate citrate buffer pH 4 as a blank, and the absorbance was detected. Drug content was calculated from the calibration curve equation (Eq. 2):

\[
y = 0.112x. \quad (2)
\]

**In vivo study**

**Experimental animals and ethical approval**

Thirty male balb-c mice (25 ± 5 g) aged 6 weeks were obtained from the Animal Facility of Nahda University in Beni Suef, Egypt. The mice were divided into six groups (\( n = 5 \)), housed in separate cages, and maintained on 60% (high-fat diet) of standard forage mixed with 4% milk powder and water ad libitum barring the normal (undiseased) group that allowed to access a standard forage. Mice were kept at room temperature maintained at 24°C ± 2°C and 12 hours light (6:00 to 18:00 hours) and dark (18:00–6:00 hours) cycles approximately (El-Menshawe et al., 2018). The in vivo study protocol was done as stated by the guidelines consented by the Pharmacology and Toxicology Department, Faculty of Pharmacy at Beni Suef University, Egypt. In addition, it was based on the National Institutes of Health Guide for Care and Use of Laboratory Animals recommendations (publication no. 85–23, revised 1985) (Albash et al., 2019; El-Menshawe et al., 2018). The animal protocol was approved by BSU-IACUC reviewers with approval number 022–351.

**Experimental protocol**

The six main groups of mice (\( n = 5 \)) were classified as the following: Group I, control diseased; Group II, treated with plain
emulgel; Group III, treated with metformin HCl emulgel; Group IV, treated with metformin HCl cholate-based nanovesicles emulgel; Group V, treated with metformin HCl cholate-based nanovesicles emulgel including DMS as a penetration enhancer (2% w/v) and Group VI as a normal control. Mice’s abdominal skin area (3 cm²) was shaved using a razor (Wu et al., 2009) and then groups (II-V) were treated topically (according to each group) once daily for 1 month (El-Menshawe et al., 2018; Picchi et al., 2011; Popescu et al., 2013). Statistics was determined using Graph Pad Prism edition 6.0 for Windows, Graph Pad Software (San Diego, CA).

Measurement of food intake

The amount of mice food intake was estimated weekly by subtracting the left-over feed from the total weight of the feed given throughout the week for each group. Then, the total average food intake per month was calculated (El-Menshawe et al., 2018).

Measurement of average body weight

Mice’s body weight was determined using Mettler balance (Toledo Type BD6000, GmbH; Greifensee, Switzerland) at the finale of the experiment (after 1 month). The amount of weight gain was computed by subtracting the average body weight at the finale of the trial from the average body weight on day 1 for each group. The percentage of weight change was calculated from the following equation (Eq. 3) (El-Menshawe et al., 2018):

\[ \text{Weight change} \% = \left( \frac{\text{Amount of weight gain after one month}}{\text{body weight on day 1}} \right) \times 100 \% \]  (3)

Blood collection and biochemical assays

Mice fasted overnight and then blood samples were amassed from the retro-orbital plexus vein under inhaled diethyl ether anesthesia. Samples were centrifuged via laboratory centrifuge (Model SM 902B, Surgifriend Medicals, England, UK) at 10,000× g for 20 minutes; then, the supernatant serum was seceded and transferred immediately to Eppendorf tubes (Tan et al., 2014). The lipid profile data (cholesterol, TG) and HDL-c (high-density lipoprotein) were evaluated from the serum samples analysis, while the Friedewald and Iranian LDL-c (low-density lipoprotein) were calculated using Equations 4 and 5 (Nauck et al., 2002), respectively. In addition, the VLDL-c (very-low-density lipoprotein) was determined by subtracting the sum of HDL-c and LDL-c from the total cholesterol (TC). The coronary risk index (CRI = TG/HDL-c) and the atherogenic index (AI = LDL-c/ HDL-c) were also determined (Kwon et al., 2003)

\[ \text{LDL-c} = [\text{TC} - (\text{HDL-c} + (\text{TG}/5))] \]  (4)

\[ \text{LDL-c (Iranian)} = \left[ \frac{(\text{TC}/1.19)+ (\text{TG}/1.19)- (\text{HDL-c}/1.1) - 38}{2} \right] \]  (5)

The serum samples were analyzed for fasting glucose and insulin content. HOMA-IR (homeostatic model assessment for insulin resistance) was calculated as )HOMA-IR= (insulin*glucose)/405 ((Cutfield et al., 2003; Majid et al., 2017), while quantitative insulin sensitivity check index (QUICKI) was determined using Equation 6 (Cutfield et al., 2003) to evaluate the insulin resistance ability of the experimental mice.

\[ \text{QUICKI} = \left( \frac{1}{\log \text{glucose} + \log \text{insulin}} \right) \]  (6)

The liver enzymes and AST and ALT levels were determined in addition to TNF-α for all the mice by analyzing the serum samples to help diagnosing NAFLD (Neuman et al., 2014; Obika and Noguchi, 2011).

Hepatic weight and morphology

Mice were slew under inhaled diethyl ether anesthesia by cervical displacement at the end of the trial. Mice’s livers were dissected, weighed, and then fixed in a 10% formalin/saline solution. After that, samples were sectioned, entrenched in paraffin, and then stained with hematoxylin and eosin for histological evaluation (magnification × 100) (Tag, 2015).

RESULTS Standard calibration curve

The standard calibration curve of metformin HCl in the buffer solution (pH 4) displayed a linear relationship between the drug concentration and the UV absorption over all the concentration ranges (1–8 µg/ml), consistent with Beer-Lambert law. The regression equation and the coefficient of determination (\(R^2\)) are exemplified in Figure 1.

Morphology of metformin HCl cholate-based nanovesicles by TEM

The vesicles appeared sphere-shaped and self-closed. The particles’ surface was coarse, and no agglomeration was noticed (Fig. 2).

Zeta size and potential of metformin HCl cholate-based nanovesicles

The zeta size of the prepared cholate-based nanovesicles formulation was 235 ± 2.7 nm while zeta potential was found (~40 ± 5.54 mV) (Fig. 3).

Characterization of metformin HCl cholate-based nanovesicles emulgel

The cholate-based nanovesicles emulgel of metformin HCl was clear, white, and homogenous even after storage for 15 days at room temperature (25°C); it showed no change in clarity or homogeneity. The pH detected was 4 (within the normal skin physiological range).

Figure 1. Standard calibration curve of metformin HCl buffer solution (pH 4).
Rheology study of metformin HCl cholate-based nanovesicles emulgel

The cholate-based nanovesicles emulgel of metformin HCl showed a perfect pseudoplastic thixotropic behavior (Fig. 4a and b). In Figure 4c, by plotting log viscosity versus the log of the shear rate, this increased the rate of shear yielded in decreasing the viscosity and vice versa (inverse relationship). The hysteresis loop (the area fenced between the up and down curve) was almost negligible. The rheology parameters of the formulation are clarified in Table 1.

Spreadability of metformin HCl cholate-based nanovesicles emulgel

The spreadability of metformin HCl cholate-based nanovesicles emulgel was 3.65 ± 0.5 g/cm².

Extrudability of metformin HCl cholate-based nanovesicles emulgel

The extrusion conduct of the prepared emulgel formulation was 5.7 ± 0.31 g/cm².

Drug content determination of metformin HCl cholate-based nanovesicles emulgel

The actual metformin HCl content of the formulation was found (98.7%).

In vivo study Measurement of food intake and average body weight

The amount of food intake decreased with metformin HCl treatment (Table 2), while the total percentage of weight gain showed a significant increase ($p < 0.0001$) in all groups compared to the normal group (group VI: 11.67% ± 12.21%), whereas only groups IV, V, and VI showed a significant decrease ($p < 0.0001$) compared to the control group (group I: 59.36% ± 13.23%) (Table 2).

Blood collection and biochemical assays

Despite being the mice treated topically, a valued systemic effect was noticed in the serum analysis results. Metformin HCl treatment showed no significant enhancement in TC levels (Table 3) in comparison with the control group (group I) (307.66 ± 25.09 mg/dl). On the other hand, TG decreased significantly ($p < 0.0001$) for both groups IV (124.17 ± 7.79 mg/dl) and V (121.93 ± 3.55 mg/dl) in addition to the normal group (VI) (72.95 ± 3.84 mg/dl) in comparison with the control group (I) (323.52 ± 39.80 mg/dl) (Table 3) with significant increase for groups I, II, and III compared to
Table 1. Rheology parameters of metformin HCl bilosomal emulgel at different shear rates and shear stresses.

<table>
<thead>
<tr>
<th>Time interval (Second)</th>
<th>Shear rate(second⁻¹)</th>
<th>Shear stress (Pa)</th>
<th>Torque %</th>
<th>Speed</th>
<th>Viscosity (Cp)</th>
</tr>
</thead>
<tbody>
<tr>
<td>00:30</td>
<td>75.00</td>
<td>443.40 ± 20.45</td>
<td>22.60</td>
<td>10.00</td>
<td>591.20 ± 27.31</td>
</tr>
<tr>
<td>00:30</td>
<td>150.00</td>
<td>592.50 ± 7.06</td>
<td>30.20</td>
<td>20.00</td>
<td>395.00 ± 4.71</td>
</tr>
<tr>
<td>00:30</td>
<td>225.00</td>
<td>682.80 ± 1.95</td>
<td>34.80</td>
<td>30.00</td>
<td>303.50 ± 0.88</td>
</tr>
<tr>
<td>00:30</td>
<td>375.00</td>
<td>799.10 ± 3.01</td>
<td>41.20</td>
<td>50.00</td>
<td>212.20 ± 0.89</td>
</tr>
<tr>
<td>00:30</td>
<td>450.00</td>
<td>872.40 ± 4.07</td>
<td>44.50</td>
<td>60.00</td>
<td>193.90 ± 0.91</td>
</tr>
<tr>
<td>00:30</td>
<td>750.00</td>
<td>966.30 ± 6.40</td>
<td>51.02</td>
<td>100.00</td>
<td>89.01 ± 0.79</td>
</tr>
<tr>
<td>00:30</td>
<td>450.00</td>
<td>860.00 ± 6.86</td>
<td>43.80</td>
<td>60.00</td>
<td>191.10 ± 1.53</td>
</tr>
<tr>
<td>00:30</td>
<td>375.00</td>
<td>788.10 ± 4.05</td>
<td>40.20</td>
<td>50.00</td>
<td>210.20 ± 1.09</td>
</tr>
<tr>
<td>00:30</td>
<td>225.00</td>
<td>640.90 ± 5.72</td>
<td>32.70</td>
<td>30.00</td>
<td>284.90 ± 2.52</td>
</tr>
<tr>
<td>00:30</td>
<td>150.00</td>
<td>548.00 ± 4.56</td>
<td>27.90</td>
<td>20.00</td>
<td>365.40 ± 3.02</td>
</tr>
<tr>
<td>00:30</td>
<td>75.00</td>
<td>423.20 ± 5.66</td>
<td>21.60</td>
<td>10.00</td>
<td>564.20 ± 7.55</td>
</tr>
</tbody>
</table>

Values were expressed as mean ± SD, n = 3.

Table 2. Effect of metformin HCl bilosomal emulgel on the body weight, liver weight, and food intake of balb-c mice after 1 month of treatment.

<table>
<thead>
<tr>
<th>Groups items</th>
<th>Control group (I)</th>
<th>Plain emulgel group (II)</th>
<th>Metformin HCl emulgel group (III)</th>
<th>Metformin HCl bilosomal emulgel (IV)</th>
<th>Metformin HCl bilosomal emulgel with penetration enhancer (V)</th>
<th>Normal group (VI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Initial body weight (g)</td>
<td>25.31 ± 1.77</td>
<td>24.76 ± 2.41</td>
<td>24.29 ± 1.97</td>
<td>24.75 ± 2.44</td>
<td>25.54 ± 2.29</td>
<td>25.23 ± 1.75</td>
</tr>
<tr>
<td>Final body weight (g)</td>
<td>40.16 ± 0.87</td>
<td>39.35 ± 2.00</td>
<td>38.69 ± 2.33</td>
<td>33.55 ± 5.02</td>
<td>34.15 ± 4.05</td>
<td>28.04 ± 1.65</td>
</tr>
<tr>
<td>Body weight gain (g)</td>
<td>14.85 ± 2.32</td>
<td>14.59 ± 3.84</td>
<td>14.40 ± 2.87</td>
<td>8.79 ± 6.18</td>
<td>8.61 ± 4.78</td>
<td>2.81 ± 2.69</td>
</tr>
<tr>
<td>% of weight gain</td>
<td>59.36 ± 13.23a</td>
<td>60.58 ± 22.62a</td>
<td>60.08 ± 15.29a</td>
<td>36.95 ± 27.26ab</td>
<td>34.59 ± 20.64b</td>
<td>11.67 ± 12.21b</td>
</tr>
<tr>
<td>Liver weight (g)</td>
<td>3.38 ± 9.01</td>
<td>3.77 ± 8.81</td>
<td>3.82 ± 6.93</td>
<td>2.44 ± 11.02</td>
<td>2.63 ± 0.56</td>
<td>1.95 ± 0.48</td>
</tr>
<tr>
<td>Average weekly food intake (g)</td>
<td>35.76 ± 5.36</td>
<td>36.33 ± 1.91</td>
<td>34.49 ± 3.04</td>
<td>29.46 ± 4.91</td>
<td>31.69 ± 4.89</td>
<td>29.19 ± 5.08</td>
</tr>
</tbody>
</table>

Values were expressed as mean ± SE, n = 3.
a has a significant difference at p < 0.0001, when compared with control model (Group I) values.
b has a significant difference at p < 0.0001, when compared with normal group (Group VI) values.

LDL-c (Friedewald and Iranian) showed a significant decrease ($p < 0.0001$) for groups IV, V, and VI in comparison with the control group (group I). While only groups I, II, and III showed a significant increase compared with the normal group (group VI) (Table 3). On the other hand, VLDL-c showed no significance ($p > 0.0001$) compared with the control and normal groups. Increasing HDL-c level leads to an improvement in the CRI; this matches the results shown in Table 3. Briefly, the serum lipid profile data showed an overall enhancement after treatment with the cholate-based nanovesicles emulgel of metformin HCl (Fig. 5).

Fasting glucose level (mg/dl) showed a significant decrease ($p < 0.0001$) in groups IV, V, and VI compared to group I (control group) (Table 3). Fasting insulin level (uIU/ml) showed no significant change among all the groups ($p > 0.0001$) as clarified in Table 3.

ALT showed a normal range all over the groups (Table 4) (Hadizadeh et al., 2017). AST results showed a significant increase ($p < 0.0001$) for groups I, II, and III regarding the normal group (129.12 ± 6.60 U/l), while groups IV, V, and VI showed a significant decrease ($p < 0.0001$) in comparison to the control group (329.90 ± 19.06 U/l). Table 4 displays the calculated AST/ALT ratio of the results (Hadizadeh et al., 2017; Sporea et al., 2018). The results showed the significant lowering effect of metformin HCl cholate-based nanovesicles emulgel on the AST enzyme.

Groups I (control group), II, and III presented a significant increase ($p < 0.0001$) in serum TNF-α (1,297.56 ± 25.32 pg/ml) compared to the normal group (731.63 ± 9.58 pg/ml) (Table 4) that points to the incidence of NAFLD. On the other hand, the metformin HCl cholate-based nanovesicles emulgel with and without the addition of the penetration enhancer (DMS) showed a significant decrease ($p < 0.0001$) weighed against the control group, confirming the topical improvement effect of metformin HCl in treating NAFLD.

Hepatic weight and morphology

Histopathology of NAFLD infected liver usually shows numerous fat vacuoles with mild to moderate fibrosis (Nakamura and Terauchi, 2013; Nascimbeni et al., 2018; Santhekadur et al., 2018; Takahashi and Fukusato, 2014). Histopathological examination of the studied groups is elucidated in Figure 6a–f. Group I and II (control and plain emulgel groups) showed copious decrease ($p < 0.0001$) in comparison to the control group (329.90 ± 19.06 U/l). Table 4 displays the calculated AST/ALT ratio of the results (Hadizadeh et al., 2017; Sporea et al., 2018). The results showed the significant lowering effect of metformin HCl cholate-based nanovesicles emulgel on the AST enzyme.

Groups I (control group), II, and III presented a significant increase ($p < 0.0001$) in serum TNF-α (1,297.56 ± 25.32 pg/ml) compared to the normal group (731.63 ± 9.58 pg/ml) (Table 4) that points to the incidence of NAFLD. On the other hand, the metformin HCl cholate-based nanovesicles emulgel with and without the addition of the penetration enhancer (DMS) showed a significant decrease ($p < 0.0001$) weighed against the control group, confirming the topical improvement effect of metformin HCl in treating NAFLD.
Table 3. Effect of metformin HCl bilosomal emulgel on the blood sugar and lipid profile in balb-c mice after 1 month of treatment.

<table>
<thead>
<tr>
<th>Groups</th>
<th>Control group (I)</th>
<th>Plain emulgel group (II)</th>
<th>Metformin HCl emulgel group (III)</th>
<th>Metformin HCl bilosomal emulgel (IV)</th>
<th>Metformin HCl bilosomal emulgel with penetration enhancer (V)</th>
<th>Normal group (VI)</th>
</tr>
</thead>
</table>
| TC (mg/dl) | 307.66 ± 25.09
a | 313.88 ± 34.73
a | 303.56 ± 50.53
a | 275.69 ± 26.50
a | 243.36 ± 22.58
a | 144.10 ± 13.65
a |
| TG (mg/dl) | 323.52 ± 39.80
a | 303.16 ± 38.48
a | 259.95 ± 30.05
b | 124.17 ± 7.99
b | 121.93 ± 3.55
b | 72.95 ± 3.84
b |
| HLDL (mg/dl) | 101.72 ± 8.12 | 103.20 ± 7.61 | 111.29 ± 12.76 | 208.94 ± 37.01
b | 190.02 ± 18.91
b | 94.88 ± 3.70 |
| LDL-c (Friedewald) (mg/dl) | 141.23 ± 15.01
b | 150.05 ± 41.51
b | 140.28 ± 33.75
b | 41.91 ± 13.03
b | 28.96 ± 19.26
b | 34.63 ± 15.87
b |
| LDL -c (Iranian) (mg/dl) | 298.33 ± 35.68
b | 291.50 ± 38.57 | 252.74 ± 46.64
b | 69.07 ± 10.05
b | 57.94 ± 15.09
b | 35.23 ± 14.68 |
| VLDL-c (mg/dl) | 64.70 ± 7.96 | 60.63 ± 7.69 | 51.99 ± 6.01 | 24.83 ± 1.56 | 24.39 ± 0.71 | 14.59 ± 0.77 |
| AI | 2.06 ± 0.21 | 2.16 ± 0.51 | 1.69 ± 0.17 | 0.40 ± 0.13 | 0.30 ± 0.13 | 0.54 ± 0.19 |
| CRI | 3.06 ± 0.21 | 3.16 ± 0.51 | 2.69 ± 0.17 | 1.40 ± 0.13 | 1.30 ± 0.13 | 1.54 ± 0.19 |
| Glucose (mg/dl) | 203.98 ± 23.69
b | 186.62 ± 14.07
b | 163.45 ± 18.51 | 115.04 ± 9.44
b | 115.27 ± 6.73
b | 109.38 ± 8.40 |
| Insulin (uIU/ml) | 13.92 ± 4.43 | 10.98 ± 3.99 | 9.81 ± 3.03 | 7.69 ± 1.75 | 7.96 ± 1.48 | 2.99 ± 0.25 |
| HOMA-IR | 7.99 ± 3.10 | 5.01 ± 1.79 | 4.48 ± 2.04 | 2.07 ± 0.39 | 2.26 ± 0.44 | 0.82 ± 0.13 |
| QUICKI | 0.31 ± 0.03 | 0.31 ± 0.01 | 0.32 ± 0.01 | 0.35 ± 0.01 | 0.34 ± 0.00 | 0.40 ± 0.01 |

Values were expressed as mean ± SE, n = 5.
TC, total cholesterol; TG, triglycerides; HLDL, high-density lipoprotein; LDL-c, low-density lipoprotein cholesterol; VLDL-c, very low-density lipoprotein cholesterol; AI, atherogenic index; CRI, coronary risk index; HOMA-IR, homeostatic model assessment for insulin resistance; QUICKI, quantitative insulin sensitivity check index.

*a* has a significant difference at p < 0.0001, when compared with model control (Group I) values.

*b* has a significant difference at p < 0.0001, when compared with normal group (Group VI) values.

fat vacuoles with moderate fibrosis owed to NAFLD (Fig. 6a and b). Group I showed congestion of the hepatic blood vessels too. Group III (Fig. 6c) exhibits no enhancement in fat vacuoles or even fibrosis than the control group (group I).

On the other hand, the groups treated with metformin HCl cholate-based nanovesicles emulgel (IV and V) perceived a manifest diminution in the number of hepatic fat vacuoles alongside fibrosis enhancement (Fig. 6d and e). Still, it is hard to say that healthy cells are back to normal as those appearing in the normal group (VI) (Fig. 6f) which showed a healthy liver confirming the experimental model’s validity.

**DISCUSSION**

Cholate-based vesicles are spherical, 5–200 nm in size, and can be uni- or multilamellar. In general, it consists of two layers; the inner layer consists of hydrophilic drugs and/or antigens, and the outer layer consists of bile salts (cholates) and/or hydrophobic drugs. Materials used in the formulation of its encompass are mainly nonionic surfactants and bile salts; lipids such as cholesterol are also included. It involves nonionic surfactants and exhibits a better quality of transdermal delivery than other nanovesicles (Al-Mahallawi et al., 2015). Bile salts produce extremely stable vesicles for transdermal distribution by acting as electrostatic stabilizers and edge activators with fluidizing effects (El Zaafarany et al., 2010). Bilosomes can be prepared by the solvent vaporization method (Al-Mahallawi et al., 2015).

TEM imaging of metformin HCl cholate-based nanovesicles fortified its successful nanospherical configuration (64.85 ± 7.14 nm as clarified in (Fig. 2)).

A zeta potential of −40 ± 5.54 mV (Fig. 3) reflects the vesicle’s stability as zeta potential > ±30 mV; zeta potential value around ±30 mV designates the vesicle’s electric repulsion and pleasant stability with no aggregation upon storage (Badria and Mazyed, 2020). The bile salt content of the formulation may cause the resulting negative charge due to its anionic nature and strongly acidic taurine group, which can enhance the cholate-based nanovesicles skin permeation (Chen-yu et al., 2012).

The clarity, homogeneity, and pH of the prepared cholate-based nanovesicles emulgel of metformin HCl declares its safety for skin application with no prediction of irritation,
The large diameter in spreadability determination exhibits better skin absorption on a larger skin area (Dhawan et al., 2014). The extrusion conduct of an emulgel formulation is a worthy feature for patient acceptance and application duration. The results verified the appropriateness of the developed formulation for topical application. The formulation drug content (98.7%) meets the terms of the official necessities (90% to 110% of the label claim) (Martins and Farinha, 1998).

NAFLD can be defined as steatosis of the liver deprived of liver injuries, such as inflating the hepatocytes or fibrosis. It is described as a disorder where >5% of hepatocytes show macroscopic steatosis under light microscopy in the privation of other causes of liver impairment (Byrne, 2010). It is diagnosed by the appearance of liver fat vacuoles, as recognized by imaging or histology, in the lack of triggering factors of liver fat deposition. Hepatic steatosis, inflammation, and liver cell destruction (swelling) with or without fibrosis are all symptoms of NASH (Valls et al., 2006). NAFLD is more dominant in males than females for unidentified explanations (DiStefano, 2020).

TNF-α partakes in NAFLD progress as it wields many proinflammatory possessions and prompts pathogenic pathways. TNF-α upsurges the serum TG, lowers the HDL-c, and raises proinflammatory possessions and prompts pathogenic pathways. TNF-α may correspondingly endorse hepatocyte death aiding in the pathophysiology of hepatic fibrosis (Zhang et al., 2013).

Metformin’s HCl role in NAFLD treatment has been examined in numerous recent studies, many of which focused on the liver’s histology and liver enzymes besides its role in decreasing glucose production in the liver (Hundal et al., 2000, Li et al., 2013; Viollet and Foretz, 2013). Furthermore, metformin HCl suppresses TNF-α (Hammad et al., 2021) which was noticeably elevated in NAFLD and worsened it (Ajamal et al., 2014; Yang and Seki, 2015). In addition, its augmenting effect plummeted the crucial risk factors for NAFLD (obesity and insulin resistance) (Hundal and Inzucchi, 2003).

The amount of food intake decreased with metformin HCl treatment (Table 2) due to its known effect on decreasing food appetite (Kim et al., 2016; Lv et al., 2012; Matsu et al., 2010). Concerning balb-c mice, the change in body weight is generally negligible; it is so-called the obesity-resistant strain (Farrell et al., 2014; Kim et al., 2011; Nishikawa et al., 2007). Despite that, the total percentage of weight gain showed a significant decrease ($p < 0.0001$) compared to the control (Table 2).

![Figure 6.](image) Histology micrograph of liver tissue; hematoxylin and eosin (magnification × 100). (a) group I (control group); (b) group II (plain emulgel treated); (c) group III (metformin HCl emulgel treated); (d) group IV (metformin HCl cholate-based nanovesicles emulgel treated); (e) group V (metformin HCl cholate-based nanovesicles emulgel including penetration enhancer treated); (f) group VI (normal group).

Table 4. Effect of metformin HCl bilosomal emulgel on the liver enzymes and TNF alpha in Balb-C mice after 1 month of treatment.

<table>
<thead>
<tr>
<th>Groups/items</th>
<th>Control group (I)</th>
<th>Plain emulgel group (II)</th>
<th>Metformin HCl emulgel group (III)</th>
<th>Metformin HCl bilosomal emulgel (IV)</th>
<th>Metformin HCl bilosomal emulgel with penetration enhancer (V)</th>
<th>Normal group (VI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>AST (U/l)</td>
<td>329.90 ± 19.06b</td>
<td>276.69 ± 36.10b</td>
<td>231.79 ± 2.24b</td>
<td>173.69 ± 8.13b</td>
<td>169.08 ± 10.53b</td>
<td>61.12 ± 4.54b</td>
</tr>
<tr>
<td>ALT (U/l)</td>
<td>81.79 ± 5.81</td>
<td>83.09 ± 5.27</td>
<td>69.78 ± 9.34</td>
<td>47.98 ± 3.77</td>
<td>47.49 ± 4.59</td>
<td>44.29 ± 2.64</td>
</tr>
<tr>
<td>AST/ALT</td>
<td>4.14 ± 0.44</td>
<td>3.33 ± 0.35</td>
<td>3.49 ± 0.38</td>
<td>3.67 ± 0.18</td>
<td>3.75 ± 0.54</td>
<td>1.39 ± 0.12</td>
</tr>
<tr>
<td>TNF alpha (pg/ml)</td>
<td>1,293.69 ± 25.32b</td>
<td>1,293.05 ± 21.82b</td>
<td>1,207.68 ± 62.67b</td>
<td>780.73 ± 32.25</td>
<td>769.35 ± 32.86</td>
<td>731.63 ± 9.58</td>
</tr>
</tbody>
</table>

AST, aspartate aminotransferase; ALT, alanine aminotransferase; and TNF alpha, tumor necrosis factor. Values were expressed as mean ± SE, $n = 5$.

b has a significant difference at $p < 0.0001$, when compared with model control (Group I) values.

b has a significant difference at $p < 0.0001$, when compared with normal group (Group VI) values.

whereas highly basic or acidic pH application on the skin may cause extreme irritation, dryness, or even erythema (El-Menshawe et al., 2018; El-Ridy et al., 2018; Mohamed et al., 2019).

The rheological conduct of a semisolid pharmaceutical preparation is crucial for its quality control (Seoane-Viaño et al., 2021). It indicates the possible physical or chemical changes during and after the formulation process. Figure 4a and b shows shear thinning behavior ($N < 1$) that increases the skin absorption area giving a good spreadability to the emulgel (Dhawan et al., 2014; Mohamed et al., 2019). The negligible hysteresis loop area corresponds to the emulgel rapid recovery after eliminating the shear rate (Gupta et al., 2012; Mohamed et al., 2019).
Despite being the mice treated topically, a valued systemic effect was noticed in the serum analysis results. That can be attributed to the cholate-based nanovesicles nanosize, ultraflexibility (Aziz et al., 2019), and flash permeation ability (Aziz et al., 2019; Salem et al., 2022) even without using a permeation enhancer that came besides its liver targeting characteristics (El-Nabawee et al., 2021).

TG decreased significantly as metformin HCl affected the TG mainly with a negligible effect on the TC (Sin et al., 2011; Wulflele et al., 2004; Xu et al., 2015); also it enhances the lipid profile by increasing HDL-C and decreasing LDL-C and VLDL (Alkuraishy and Al-Gareeb, 2015; Ghatak et al., 2011). The results agreed with this indicating the enhancing effect of metformin HCl cholate-based nanovesicles emulgel on HDL-c (Fig. 5).

Increasing HDL-c level leads to an improvement in the AI and consequently in the CRI, matching the results shown in Table 3. Briefly, the serum lipid profile data showed an overall enhancement after treatment with the cholate-based nanovesicles emulgel of metformin HCl (Fig. 5). Insulin resistance is also a crucial sign of NAFLD, as it leads to abated liver production of glucose and lessened glucose uptake (Muoio and Newgard, 2008). Accordingly, the determination of glucose, insulin, HOMA-IR, and QUICKI helps in NAFLD assessment (Motamed et al., 2016). Metformin HCl lowers the glucose level by decreasing its intestinal absorption (Viollet and Foretz, 2013), increasing its uptake from the blood into the tissues and decreasing its production from the liver (Hundal et al., 2000; Viollet and Foretz, 2013). Metformin also affects the insulin requirements for glucose discarding (increasing insulin sensitivity) without affecting the serum insulin levels (Gaggini et al., 2013; Hadizadeh et al., 2017).

The optimal limit point (the cut-off point) for HOMA-IR in the NAFLD diagnosis is >1.79, while for QUICKI, it is <0.347 (Salgado et al., 2010). Generally, a higher value of HOMA-IR and a lower value of QUICKI increase the insulin resistance risk (Motamed et al., 2016). HOMA-IR and QUICKI results revealed the metformin HCl enhancement effect on NAFLD by increasing insulin sensitivity (Losono et al., 2010) as clarified in Table 3.

ALT and AST results are shown (Table 4 was as predicted, as a marked elevation in ALT level is not common in NAFLD but is mainly associated with liver steatosis (Hadizadeh et al., 2017; Pearce et al., 2013). AST elevation can be used as an independent marker for NAFLD, mainly when the values are twice the normal levels (Hadizadeh et al., 2017). Recently, AST/ALT ratio became used for NAFLD diagnosis; the more of this ratio (>1.5), the more possibility of having fatty liver disease (Hadizadeh et al., 2017; Sporea et al., 2018). AST/ALT ratio confirms the formulation’s influential role in enhancing NAFLD.

TNF-α, with its proinflammatory effect, plays a pivotal role in NAFLD progression (Hadizadeh et al., 2017; Jovinge et al., 1998) through different mechanisms as it increases the serum levels of TG (Jovinge et al., 1998) and decreases the HDL-c levels and insulin sensitivity (Tacer et al., 2007). Besides that, TNF induces apoptosis and proliferation in hepatic cells leading to liver fibrosis (Galle, 1997; Yang and Seki, 2015). Elevated serum levels of TNF-α can be related to NAFLD, and normalization of its results enhances insulin sensitivity and NAFLD (Ajmal et al., 2014; Hadizadeh et al., 2017). The decreasing effect of the prepared metformin emulgel on the TNF-α confirms the topical improvement effect of metformin HCl in treating NAFLD.

Nevertheless, the difference in liver weight among the groups was insignificant (p > 0.0001) (Table 2), and metformin HCl cholate-based nanovesicles emulgel treated groups parades an acceptable reduction in the liver weight put side by side with the control group. Histopathological of NAFLD-infected liver usually shows numerous fat vacuoles with mild to moderate fibrosis (Nakamura and Terauchi, 2013; Nascimbeni et al., 2018; Santhekadur et al., 2018; Takahashi and Fukusato, 2014). Histopathological examination of the studied groups is elucidated in Figure 6a–f revealing the therapeutic effect of metformin HCl cholate-based nanovesicles emulgel in the topical treatment of NAFLD and signifying the success of liver targeting by metformin HCl cholate-based bile salts (El-Nabawee et al., 2021).

CONCLUSION
A cholate-based nanovesicles emulgel of metformin HCl was fruitfully prepared and assessed to open a new gateway to use metformin HCl in the transdermal treatment of NAFLD. The TEM imaging verified a successful formulation of nano cholate-based bile salts, and its stability was confirmed by the zeta potential result and then incorporated into an emulgel. Furthermore, the prepared cholate-based nanovesicles emulgel showed suitable clarity, homogeneity, pH, spreadability, extrudability, and drug content. In addition, the rheology behavior was perfect thixotropic as demanded by a transdermal formulation. Furthermore, the in vivo study on bab–c mice showed impressive results in treating NAFLD transdermally. The overall consequences of these findings highlight the cholate-based nanovesicles emulgel as a promising formulation for acceptable level of transdermal treatment of NAFLD.

STATISTICAL ANALYSIS
The significance of differences was ascertained by a two-way analysis of variance (ANOVA) using Graph Pad Prism edition 6.0 for Windows, Graph Pad Software (San Diego, CA). The results were stated in mean ± SE, and p-value < 0.0001 was deemed statistically significant.

ACKNOWLEDGMENTS
The authors are grateful for Nahda University in Beni Suef Central Lab for providing the amenities to elicit this work.

AUTHOR CONTRIBUTIONS
All authors made substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; took part in drafting the article or revising it critically for important intellectual content; agreed to submit to the current journal; gave final approval of the version to be published; and agree to be accountable for all aspects of the work. All the authors are eligible to be an author as per the international committee of medical journal editors (ICMJE) requirements/guidelines.

FINANCIAL SUPPORT
There is no funding to report.

CONFLICTS OF INTERESTS
The authors report no conflicts of interest.
ETHICAL APPROVALS

The in vivo study protocol was done as stated by the guidelines consented by the Pharmacology and Toxicology Department, Faculty of Pharmacy at Beni Suef University, Egypt. In addition, it was based on the National Institutes of Health Guide for Care and Use of Laboratory Animals recommendations. The animal protocol was approved by BSU-IACUC reviewers with approval number 022–351.

DATA AVAILABILITY

All data generated and analyzed are included in this research article.

PUBLISHER’S NOTE

This journal remains neutral with regard to jurisdictional claims in published institutional affiliation.

REFERENCES


Hadinzadeh F, Faghhihami E, Adibi P. Nonalcoholic fatty liver disease: diagnostic biomarkers. World J Gastrointest Pathophysiol, 2017; 8:11.

Hammad AM, Ibrahim YA, Khidair SI, Hall FS, Alfaraj M, Jarrar Y, Abed AF. Metformin reduces oxandrolone-induced depression-like behavior in rats via modulating the expression of IL-1β, IL-6, IL-10 and TNF-α. Behav Brain Res, 2021; 414:113475.


Salem et al. / Journal of Applied Pharmaceutical Science 13 (07); 2023: 258-269


How to cite this article: